For years, Plavix and Lipitor, two of the most lucrative prescription medications in the history of the American drug market, have constituted quite a one-two punch.  Now, as Plavix loses its patent protection and Lipitor faces competition from multi-source generics, it’s an important time for consumers and benefits managers to understand how the transition from brand to generic will affect drug prices going forward.

As Pharmacists United for Truth and Transparency explained on AARP’s Inside E Street, Pfizer previously offered massive rebates to pharmacy benefits managers (PBMs), the third party administrators of prescription drug programs, to give preferential formulary treatment to brand name Lipitor.  In doing so, Pfizer and a number of PBMs kept brand name Lipitor profitable and expenses higher than needed for many employers and consumers.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?

Dig Deeper



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.